Literature DB >> 6094433

Cefotaxime and desacetyl-cefotaxime blood levels in hepatic dysfunction.

W Graninger, M Uihlein, P Ferenci, C Moser, A Georgopoulos.   

Abstract

Serum levels of cefotaxime and desacetyl-cefotaxime were studied in 18 patients with hepatic cirrhosis after an intravenous bolus injection of 2 g of cefotaxime. Blood levels were independent of the degree of hepatic dysfunction and did not differ from those reported in normal individuals.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6094433     DOI： 10.1093/jac/14.suppl_b.143

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

3.  Pharmacokinetics of cefotaxime and desacetylcefotaxime in patients with liver disease.

Authors:  R J Ko; F R Sattler; S Nichols; E Akriviadis; B Runyon; M Appleman; J L Cohen; R T Koda
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 4.  Antibiotics and Liver Cirrhosis: What the Physicians Need to Know.

Authors:  Caterina Zoratti; Rita Moretti; Lisa Rebuzzi; Irma Valeria Albergati; Antonietta Di Somma; Giuliana Decorti; Stefano Di Bella; Lory Saveria Crocè; Mauro Giuffrè
Journal:  Antibiotics (Basel)       Date:  2021-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.